GSK plc (GLAXF)
| Market Cap | 79.87B |
| Revenue (ttm) | 43.34B |
| Net Income (ttm) | 4.69B |
| Shares Out | n/a |
| EPS (ttm) | 1.13 |
| PE Ratio | 17.03 |
| Forward PE | 8.41 |
| Dividend | 0.82 (4.18%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 894 |
| Average Volume | 1,825 |
| Open | 19.68 |
| Previous Close | 19.77 |
| Day's Range | 19.68 - 19.68 |
| 52-Week Range | 15.54 - 22.00 |
| Beta | 0.27 |
| RSI | 60.98 |
| Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
Hong Kong to launch collaborative study on long-term effects of shingles vaccine
A Hong Kong government-owned clinical trial institute will launch a study to examine the long-term health effects of the shingles vaccine in real-world settings, collaborating with a global pharmaceut...
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences Ltd . (NASDAQ: WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency...
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.
What's Driving the Market Sentiment Around GSK?
GSK's (NYSE: GSK) short percent of float has fallen 9.68% since its last report. The company recently reported that it has 11.29 million shares sold short , which is 0.56% of all regular shares that ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
UK clears GSK’s new oral antibiotic for UTIs
Price Over Earnings Overview: GSK
Looking into the current session, GSK Inc. (NYSE: GSK) shares are trading at $39.91, after a 0.20% spike. Moreover, over the past month, the stock spiked by 2.41% , but in the past year, fell by 8.76...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P...
GSK launches advanced cancer therapies Jemperli and Zejula in India
GSK has announced the availability of its much-anticipated cancer therapies, Jemperli (dostarlimab) and Zejula (niraparib), in India, reinforcing its commitment to offering specialised treatments for ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle...
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study
Dynavax Technologies Corporation (NASDAQ: DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine...
Dynavax says shingles shot performed on par with GSK’s Shingrix in Phase 1/2 trial
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P...
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P...
GSK bid to expand Blujepa label for gonorrhea granted FDA priority review
GSK's antibiotic drug gepotidacin gets priority review by FDA
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral t...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
Drugmaker GSK lands £372m in Covid jab pact
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.